| 摘要: |
| 目的 观察免疫活化树突状细胞（DC）联合细胞因子诱导的杀伤细胞（CIK）治疗（DC-CIK 治疗）晚期结直肠癌的临 床疗效。 方法 选取 2010 年以来的Ⅳ期结直肠癌患者 90 例，随机分为两组，联合治疗组患者采用免疫活化 DC-CIK 治疗，同时行 化疗，单纯化疗组患者仅行化疗。比较两组患者的生存率、免疫功能变化，并判断免疫活化 DC-CIK 治疗的安全性。 结果 联合治 疗组 2 年及 3 年总生存率均明显高于单纯化疗组（2 年总生存率 67.6% vs 38.3%，3 年总生存率 29.8% vs 18.8%，均 P＜0.05）。单 纯化疗组患者治疗后 CD8+ 细胞比例高于治疗前（P＜0.05）；与单纯化疗组治疗后比较，联合治疗组治疗后 CD4+、CD4+/CD8+、 CD16+CD56+ 细胞比例升高，CD8+ 细胞比例明显下降，且联合治疗组治疗前后 CD4+、CD4+/CD8+、CD16+CD56+ 细胞比例亦有变化
（均 P＜0.05）。 结论 免疫活化 DC-CIK 治疗对晚期结直肠癌患者有较好的临床疗效，可改善患者的免疫抑制状态，且具有良好的 安全性。 |
| 关键词: 免疫治疗 结直肠癌 DC-CIK 活化 总生存时间 |
| DOI： |
| 分类号: |
| 基金项目:浙江省“十二五”重大科技专项;浙江省医药卫生平台资助计划 |
|
| Activated DC combined with CIK immunotherapy for patients with advanced colorectal cancer |
|
RUI Tao,WU Guoqing,XU Ji,ZHENG Aihong,WU Hao,YE Zaiyuan
|
|
Zhejiang provincial People's Hospital
|
| Abstract: |
| Objective To evaluate the efficacy of activated DC-CIK adjuvant immunotherapy for patients with advanced colorectal cancer. Methods Ninety patients with stage IV colorectal cancer were randomly assigned to receive DC-CIK immunotherapy plus chemotherapy (n=45, combined therapy group) or chemotherapy alone (n=45, chemotherapy group). The survival status, immune function and adverse effects were compared between two groups. Results Compared with chemotherapy group, the 2- and 3-year overall survival (OS) rate in combined therapy group was significantly improved (67.6% vs 38.3%, P＜0.05; 29.8% vs 18.8%, P＜0.05, respectively). After combined therapy, the mean CD4+ level, CD4+/CD8+ ratio, CD16+CD56+ level were increased and the mean CD8+ level decreased compared with those before combined therapy. No serious adverse effects were observed in 116 course of activated DC-CIK immunotherapy. Conclusion Activated DC-CIK adjuvant immunotherapy is effective for advanced colorectal cancer patients, which is associated with improved immune function of patients. |
| Key words: Immunotherapy Colorectal cancer DC-CIK Activated Overall survival |
